Battle Card: Character Biosciences $17M Series B Trigger

🚀 Battle Card: Character Biosciences

• [Cheng Zhang](), CEO & Co-Founder 📧 cheng@characterbio.com

• As a Character Biosciences sales trigger, the Series B top-up to $110M+ validates the push to accelerate AI-driven precision therapies for dry AMD and POAG. → Source

• High failure rates in polygenic disease drug development

• Limited access to integrated genomics–clinical datasets

• Primary: Data integration & management platform → Streamline clinical-genomic data workflows

• Expansion: Predictive AI modeling suite → Improve target validation accuracy

• HQ: Jersey City, NJ

• Employees: ≈ 50

• Rev: ≈ $5 M

• Website: characterbio.com

🤼 Competitive Intel

• Tempus — Genomics & AI Analytics
• Unique edge: Ultra-high-throughput sequencing & clinical AI models
• Evaluated by CEO & Head of R&D for model robustness

• Cota Healthcare — Real-World Data Platform
• Unique edge: Integrated EHR & outcomes datasets
• Evaluated by VP Clinical Ops for dataset quality

• Owkin — AI & Federated Learning
• Unique edge: Privacy-preserving multi-center model training
• Evaluated by CTO & Data Science lead for scalability

• Syapse — Real-World Evidence
• Unique edge: Proven oncology-to-ophthalmology crossover frameworks
• Evaluated by Head of Medical Affairs for regulatory support

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑❑
OFFER_BRIEF   = ❑Data integration & management platform❑
PROOF_METRIC  = ❑≈ TBD❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑punchy❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Cheng
COMPANY     = Character Biosciences
DEPT        = R&D
SIZE        = 50
BOTTLENECK  = high failure rates
EVENT       = 17M Series B Extension
DETAIL      = the $17M Series B extension
PAIN        = high failure rates in polygenic disease drug development
SRC         = https://vcnewsdaily.com/character-biosciences/venture-capital-funding/lfgmsbfctj
SIM_CO      = ≈ TBD
WIN_METRIC  = ≈ TBD
NEXT_SIZE   = ≈ TBD
EMP_EST     = ≈ 50
REV_EST     = ≈ $5M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: 50-person R&D

Cheng—noticed your R&D team is ≈ 50.

That’s when high failure rates slows growth.

We helped ≈ TBD fix this with Data integration & management platform.

Result: ≈ TBD.
Quick call?

PS—next bottleneck hits ≈ ≈ TBD.

DM ≤45 words, TONE:
Saw your post about the $17M Series B extension — high failure rates in polygenic disease drug development.  
Data integration & management platform. ≈ TBD.  
Quick chat?